What is the current price range of ibrutinib/ibrutinib?

Ibrutinib (Ibrutinib), as the world's first approved BTK inhibitor, has become one of the standard treatment options for various hematological malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). With its official launch in mainland China, the accessibility of original drugs has significantly improved. The mainstream form of ibrutinib is 140 mg capsules, and the common packaging specification is 90 capsules. In the domestic market, the current price of this drug is about RMB 10,000, and it has been included in the National Medical Insurance Category B Catalog. Patients who qualify for reimbursement can enjoy varying degrees of fee reductions, significantly reducing their financial burden.

In contrast, the price of ibrutinib in overseas markets is significantly higher, especially in the United States, where its monthly treatment cost may even exceed US$10,000. But at the same time, some overseas countries and regions have also begun to provide high-quality generic versions, especially pharmaceutical companies from India and Bangladesh. For example, the generic version launched by Yaopin International sells for only about 2,000 yuan per box of 140 mg and 112 pills, providing a more affordable alternative for patients with limited financial conditions. These generic drugs usually pass bioequivalence evaluation, and their ingredients are basically the same as the original drugs, which can significantly reduce costs while ensuring efficacy.

It should be noted that although generic drugs are cost-effective, the legality of drug purchase channels, drug quality regulatory standards and clinical safety still need to be strictly controlled. When patients choose overseas generic drugs, they must do so through formal platforms or under the advice of a doctor. They must not buy or use drugs from unknown sources without permission. Under the premise of enjoying domestic medical insurance policies, original drugs are still the first choice for many patients. However, when financial conditions are limited or medical insurance does not cover them, high-quality generic drugs have become a necessary alternative.

Reference materials:https://www.imbruvica.com/